Cytomegalovirus gastroenteritis and hepatitis
ICD-10 B25.9 · ICD-11 1A24

Mild CMV Colitis or CMV Esophagitis: What to Do When Valganciclovir Has Not Resolved Symptoms

This protocol covers the next treatment step for patients with mild CMV colitis or mild CMV esophagitis whose gastrointestinal signs and symptoms have not resolved on the initial oral regimen.

Clinical Scenario
The patient presents with mild CMV colitis or mild CMV esophagitis. Oral therapy is appropriate for mild disease, but when the therapeutic goal — resolution of gastrointestinal signs and symptoms — is not met, an alternative approach is required.
Why This Protocol Is Needed — Previous Line Failure
The preceding regimen was valganciclovir. The treatment goal of that line — resolution of gastrointestinal signs and symptoms of CMV disease, typically assessed over a 21–42 day course — was not achieved. This unmet endpoint triggers escalation to the current protocol.
Next-Line Approach — Partial Overview
This protocol involves an intravenous antiviral agent indicated when the prior oral agent has not achieved symptom resolution or when toxicity limits its use. The full regimen specifies which IV agent to use, how it is administered, and what adjunct measures accompany infusion. The clinical goal remains resolution of gastrointestinal signs and symptoms; duration is guided by the response, typically spanning several weeks.
Instant Access to Structured Evidence-Based Regimens

References

  1. Valganciclovir 900 mg PO every 12 hours can be used in patients with mild disease (AIII).
  2. Oral valganciclovir can be used in patients with mild disease (AIII).
  3. Foscarnet 60 mg/kg IV every 8 hours or 90 mg/kg IV every 12 hours (BIII)—for patients with treatment-limiting toxicities to ganciclovir or with ganciclovir resistance; or
  4. Cidofovir 5 mg/kg/week IV for 2 weeks, then 5 mg/kg IV every other week. Administer 1 L of normal saline before and, if additional fluid load can be tolerated, administer another 1 L of normal saline after cidofovir infusion. Administer probenecid 2 g PO 3 hours before each cidofovir dose followed by 1 g PO 2 hours after the dose and 1 g PO 8 hours after the dose (total of 4 g) (CI).
  5. 21–42 days or until signs and symptoms have resolved (AIII).
View source ↗